Israel - English - Ministry of Health

merck serono ltd - bisoprolol fumarate - tablets - bisoprolol fumarate 5 mg - bisoprolol - - treatment of stable chronic, moderate to severe heart failure with impaired systolic ventricular function ( ejection fraction < 35 %, determined by echocardiography) in addition to ace inhibitors and diuretics, and optionally cardiac glycosides.- hypertension- coronary heart disease (angina pectoris)

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - venlafaxine as hydrochloride - capsules - venlafaxine as hydrochloride 75 mg - venlafaxine - venlafaxine - for the treatment of depression. maintenance of recurrent depression. generalized anxiety disorder (gad) - short term and long-term. social anxiety disorder (sad).

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - venlafaxine as hydrochloride - capsules - venlafaxine as hydrochloride 150 mg - venlafaxine - venlafaxine - for the treatment of depression. maintenance of recurrent depression. generalized anxiety disorder (gad) - short term and long-term. social anxiety disorder (sad).

Israel - English - Ministry of Health

unipharm ltd, israel - memantine hydrochloride - tablets - memantine hydrochloride 10 mg - memantine - treatment of patient with moderate to severe alzheimer's disease.

Israel - English - Ministry of Health

unipharm ltd, israel - memantine hydrochloride - film coated tablets - memantine hydrochloride 20 mg - memantine - treatment of patient with moderately severe to severe alzheimer's disease.

Israel - English - Ministry of Health

novartis israel ltd - nilotinib as monohydrate - capsules - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Israel - English - Ministry of Health

novartis israel ltd - nilotinib as hydrochloride monohydrate - capsules - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

Israel - English - Ministry of Health

teva israel ltd - sitagliptin as malate - film coated tablets - sitagliptin as malate 100 mg - sitagliptin - sitagliptin teva is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. important limitations of use: sitagliptin teva should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.sitagliptin teva has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitagliptin teva.

Israel - English - Ministry of Health

teva israel ltd - sitagliptin as malate - film coated tablets - sitagliptin as malate 25 mg - sitagliptin - sitagliptin teva is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. important limitations of use: sitagliptin teva should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.sitagliptin teva has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitagliptin teva.

Israel - English - Ministry of Health

teva israel ltd - sitagliptin as malate - film coated tablets - sitagliptin as malate 50 mg - sitagliptin - sitagliptin teva is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. important limitations of use: sitagliptin teva should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.sitagliptin teva has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitagliptin teva.